Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill establishes a coordinated National Biotechnology Initiative led from the Executive Office of the President, creates a National Biotechnology Coordination Office and an interagency committee, and requires a national strategy, annual reports, and a public website. It charges participating agencies with coordinated activities across R&D, data and databases, commercialization, regulatory streamlining, biosafety/biosecurity, workforce development, and international engagement.
Regulatory streamlining: progressive fears lowered safety; conservatives favor faster approvals.
Relative to its intended legislative type, this bill is a well-specified administrative/operational statute that establishes an interagency governance structure, a coordinating office in the Executive Office of the President, concrete deliverables and timelines, and multiple accountability mechanisms.
This bill establishes a coordinated National Biotechnology Initiative led from the Executive Office of the President, creates a National Biotechnology Coordination Office and an interagency committee, and requires a national strategy, annual reports, and a public website.
It charges participating agencies with coordinated activities across R&D, data and databases, commercialization, regulatory streamlining, biosafety/biosecurity, workforce development, and international engagement.
The bill authorizes limited funding to the NSF to staff the Office, sets oversight and Comptroller General review timelines, allows convening of expert groups exempt from FACA, and sunsets the Office’s active role after 20 years.
Modest funding and administrative focus improve prospects, but complexity, regulatory implications, and stakeholder concerns lower probability without compromise amendments.
Relative to its intended legislative type, this bill is a well-specified administrative/operational statute that establishes an interagency governance structure, a coordinating office in the Executive Office of the President, concrete deliverables and timelines, and multiple accountability mechanisms. It combines operational detail with reporting and review requirements appropriate to a national coordination initiative.
Regulatory streamlining: progressive fears lowered safety; conservatives favor faster approvals.
These are examples from the analysis, not a ranked list of the most-affected groups.
Regulatory streamlining: progressive fears lowered safety; conservatives favor faster approvals.
Generally supportive of federal investment in biotechnology coordination, workforce, and biosafety, but wary of provisions that prioritize regulatory easing and commercial translation without strong safeguards.
Concerned about corporate influence, public health and environmental risks, data privacy, and the FACA exemption for expert convenings.
Would push for stronger transparency, public participation, and enforceable safeguards in implementation.
Views the bill as a pragmatic, bureaucratic effort to coordinate federal biotechnology efforts and enhance U.S. competitiveness.
Likes the emphasis on clear regulatory paths, GAO review, and annual reporting, but seeks clear budget accountability and guardrails against duplication and rushed deregulation.
Would support with modest changes to ensure transparency and fiscal clarity.
Likely supportive of measures that boost commercialization, competitiveness, and regulatory streamlining, while skeptical of creating a new White House office and expanding federal bureaucracy.
Favors the emphasis on national security and private-sector translation but will watch for federal overreach, recurring spending, and restrictions that could stifle market innovation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest funding and administrative focus improve prospects, but complexity, regulatory implications, and stakeholder concerns lower probability without compromise amendments.
The bill has not accumulated any surfaced votes yet.
Regulatory streamlining: progressive fears lowered safety; conservatives favor faster approvals.
Modest funding and administrative focus improve prospects, but complexity, regulatory implications, and stakeholder concerns lower probabil…
Relative to its intended legislative type, this bill is a well-specified administrative/operational statute that establishes an interagency governance structure, a coordinating office in the Executive Office of the Pres…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.